Kvantify, a business specializing in quantum and high-performance computing based in Denmark, is thrilled to announce its expansion to the United Kingdom. This development includes the appointment of its very own in-house drug-discovery team. Kvantify has experienced rapid growth since its founding in 2022 and has recently enlisted four new team members from Benevolent AI. The company’s team in Denmark is comprised of over 50 top-tier experts who possess a background in physics, mathematics, chemistry, and computer science. Kvantify has been providing SaaS solutions in a variety of industries, including finance, logistics, and life sciences.
The UK expansion aims to focus on the drug development industry, which is among Kvantify’s most popular offerings. The UK-based team will concentrate on using physical simulations and machine learning methods to expedite drug discovery. Kvantify has successfully developed software tools that allow organizations’ scientists to speed up their drug development projects, but many businesses lack the necessary competencies or resources to utilize these tools. With the creation of its new UK team, Kvantify is now capable of extending its services to a wider format of companies, with an offering to conduct early drug discovery through computational means.
Kvantify’s new hires include Michael Carter as Head of Drug Discovery, Giulio Mattedi as Cheminformatics Specialist, Daniela Dolciami as Senior Computational Chemist, and Rob Z as Computational Chemistry Specialist. The company is also advancing other upcoming projects, including the development of their new FAST-VQE quantum algorithm. This algorithm significantly reduces one of the significant bottlenecks in applying quantum technology to the chemistry and drug discovery space.
Additionally, Kvantify will enter a collaboration with King’s College London’s Chemistry Department. Kvantify’s co-founder, Professor Nikolaj Zinner, Head of Strategic Alliances, Nils Berglund, and Head of Drug Discovery, Dr Michael Carter, will take on visiting positions at the department, assisting them in adopting new quantum technologies and identifying use cases. Moreover, Kvantify will have access to King’s talent pool and will sponsor a PhD student in Professor Martin Ulmschneider’s section to develop new drug discovery methods and further endeavour novel approaches that are appropriate for quantum computing.
Hans Henrik Knudsen, the co-founder and CEO of Kvantify, believes that London is an ideal location that provides a nurturing ecosystem for their software solutions to thrive. The city’s vibrant tech community and access to top talent are in line with the company’s growth objectives. Kvantify has established itself as a prominent player in the Danish market and is poised to cement its position in the European market.